Crossmark

Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures

Crossref DOI link: https://doi.org/10.1007/s11096-026-02119-x

Published Online: 2026-03-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Chenning

Lyu, Liyang

Zhang, Yufan

Tian, Yingyi

Yuan, Jing

Li, Chihua

Hu, Yuanjia
Funding

Funding for this research was provided by:

Science and Technology Development Fund of Macau SAR (0049/2024/AGJ)

University of Macau (MYRG-CRG2023-00007-ICMS-IAS)
License Information

Text and Data Mining valid from 2026-03-17

Version of Record valid from 2026-03-17
More Information

Article History

Received: 25 September 2025

Accepted: 13 February 2026

First Online: 17 March 2026

Declarations

:

: The authors declare no competing interests.

: Ethics review and informed consent were waived because all analyzed data were derived from open-access repositories, aggregated clinical trial databases, and published literature that did not contain individual patient identifiers.

Document is current

Any future updates will be listed below